



Measles and Rubella Elimination Goals, Strategies and Status

ACIP February 22, 2017 Gavin Grant, MD, MPH CDC/GID/CGH















Presentation Outline

- Global Measles and Rubella Strategic Plan
- Global Situation
 - Measles
 - Rubella
- Regional elimination progress
- Strategic plan mid-term review report




























GLOBAL MEASLES AND RUBELLA

STRATEGIC PLAN 2012–2020

Vision:

Achieve and maintain a world without measles, rubella and congenital rubella syndrome

Targets and Milestones

- Targets
 - By end 2015:
 - Reduce global measles mortality by at least 95% compared with 2000 estimates
 - Achieve regional measles and rubella/CRS elimination goals
 - By end 2020:
 - Achieve measles and rubella elimination in <u>at least five</u> (of the six) WHO Regions
- Milestones
 - Reduce annual measles incidence to < 5 cases per million and maintain that level
 - ≥ 90% coverage with routine MCV1 nationally and ≥ 80% vaccination coverage in every district or equivalent administrative unit
 - — ≥ 95% coverage with M, MR or MMR during SIAs in every district or equivalent administrative unit
 - Establish a rubella/CRS elimination goal in at least 1 more WHO Region
 - Establish a target date for the global eradication of measles

Targets and Milestones

Targets

- By end 2015:
 - Reduce global measles mortality by at least 95% compared with 2000 estimates
 - Achieve regional measles and rubella/CRS elimination goals
- By end 2020:
 - Achieve measles and rubella elimination in <u>at least five</u> (of the six) WHO Regions

Milestones (by 2015)


- Reduce annual measles incidence to < 5 cases per million and maintain that level
- > 90% coverage with routine MCV1 nationally and > 80% vaccination coverage in every district or equivalent administrative unit
- – ≥ 95% coverage with M, MR or MMR during SIAs in every district or equivalent administrative unit
- Establish a rubella/CRS elimination goal in at least 1 more WHO Region
- Establish a target date for the global eradication of measles

Strategies

- High population immunity through vaccination with two doses of M and R containing vaccines
- 2. Effective surveillance, monitoring and evaluation
- 3. Outbreak preparedness and response & case management
- Communication to build public confidence and demand for immunization
- 5. Research and development

How far have we come?





Measles

Milestones

1. Coverage

Target: >90% routine nationally

Target: <u>></u>95% campaign

2. Incidence

• Target: < 5/million

3. Mortality

• Target: 95% reduction














Milestone 1- *Coverage:* Measles containing vaccine 1st dose (MCV1), 1980-2015





Source: WHO/UNICEF coverage estimates 2015 revision. July 2016 Immunization Vaccines and Biologicals, (IVB), World Health Organization. 194 WHO Member States. Date of slide: 25 July 2016.













Estimated MCV1 coverage, by country 2015



<50% (4 countries or 2%) 50-79% (38 countries or 20%) 80-89% (33 countries or 17%) 90-94% (40 countries or 21%) ≥ 95% (79 countries or 40%) Not available

Not applicable

ncerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represen

expression of any opinion whatsoever on the part of the World Health Organization

119 (61%) countries have > 90% MCV1 coverage 42 (22%) countries have < 80% MCV1 coverage

Source: WHO/UNICEF coverage estimates 2015 revision. Map production: Immunization Vaccines and Biologicals, (IVB). World Health Organization, 194 WHO Member States. Date of slide: 16 July 2016















39 Countries conducted 66 campaigns in 2015


















Milestone 2- *Incidence*: Annual reported measles cases (with MCV coverage) 1980-2015





**MCV2 estimates is only available from 2000 when global data collection started, however some countries have introduced the vaccine earlier.

194 WHO Member States. Updated on 18 July 2016














Milestone 3- *Mortality Reduction:* Decrease from 2000 Estimate


















Where we are





Rubella

- 1. Coverage
- 2. Burden of Congenital Rubella Syndrome
- 3. Vaccine introduction




















Source: WHO/UNICEF coverage estimates 2015 revision. July 2016 Immunization Vaccines and Biologicals, (IVB), World Health Organization. 194 WHO Member States. Date of slide: 16 July 2016.

*coverage estimates for the 1rst dose of rubella containing vaccine are based on WHO and UNICEF estimates of coverage of measles containing vaccine.














77

Rubella vaccine 1st dose coverage by WHO region, 1980-2015



Source: WHO/UNICEF coverage estimates 2015 revision. July 2016 Immunization Vaccines and Biologicals, (IVB), World Health Organization. 194 WHO Member States. Date of slide: 16 July 2016.

*coverage estimates for the 1rst dose of rubella containing vaccine are based on WHO and UNICEF estimates of coverage of measles containing vaccine.














Rubella Vaccination Prevents CRS: Estimates of the median incidence of CRS per 100,000 live births by country in 2010





Vynnycky E, Adams EJ, Cutts FT, Reef SE, Navar AM, et al. (2016) Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review. PLoS ONE 11(3): e0149160. doi:10.1371/journal.pone.0149160 http://journals.plos.org/plosone/article?id=info:doi/10.1371/journal.pone.0149160














Countries with rubella vaccine in the national immunization program or planned introductions in 2016





















Regional Progress












Measles and Rubella Elimination Goals by WHO Region, 2016



All Regions have measles elimination goals

Americas, European and Western Pacific Regions have rubella elimination goals













Regional Verification of Measles and Rubella Elimination, 2016

	Regional Verification Commissions Established	Elimination Achieved	
WHO Region		# of countries	% of countries
African (AFR)	No	-	-
Americas (AMR)	Yes	Measles: 36 Rubella: 36	100% <i>100</i> %
European (EUR)	Yes	Measles: 21 Rubella: 24	40% <i>45%</i>
Eastern Mediterranean (EMR)	No	-	-
South-East Asian (SEAR)	Yes	-	-
Western Pacific (WPR)	Yes	Measles: 7	19%













Regional Scorecard for Measles & Rubella Elimination (2015)

WHO Region	Elimination Target	MCV1 /MCV2 coverage	Measles/Rubella incidence (/million)	Comment
AFR	2020 – measles	74% 18%	100 5.6	Off track for 2020 goal No rubella target
AMR	2000 – measles 2010 – rubella	94% 53%	0.6 0	Measles Verified:5/2016 Rubella Verified:9/2015
EUR	2015 – measles 2015 – rubella	94% 89%	31 0.9	Off track- both
EMR	2020 – measles	76% 68%	33 3.0	Off track No rubella target
SEAR	2020 – measles	85% 71%	17 2.6	2020 goal Rubella control target
WPR	2012 – measles No date - rubella	96% 93%	35 5.1	Late; setback in 2014-15 rubella target 2020?
Global	measles rubella	85% 46%	37 ?	All Regions by 2020 5/6 Regions by 2020

Challenges to Measles-Rubella Elimination



- AMR- risk of importations
- AFR— weak immunization & health systems, reliance on campaigns
- EUR— vaccine hesitancy, susceptible adults, variable surveillance quality
- EMR– security issues that limit access; persistent low coverage in some countries
- SEAR— large federalized countries (e.g. India, Indonesia) with heterogeneous coverage and need to strengthen and expand case-based surveillance
- WPR- measles resurgence in China, Philippines

All Regions

- Need for increased visibility and political commitment to regional elimination goals
- Susceptibility gaps including among older children and adolescents
- Lack of human and financial resources
- Vaccine hesitancy














MIDTERM REVIEW OF THE GLOBAL MEASLES AND RUBELLA STRATEGIC PLAN 2012 – 2020



Major findings and conclusions (1)



- Tremendous progress made since 2001, however, neither measles nor rubella elimination on track to achieve ambitious goals
- Basic strategies articulated are sound
- Full implementation has been limited by inadequate country ownership and global political will, reflected in inadequate resources
- It is premature to set a timeframe for measles eradication at this point
 - A determination should be made, not later than 2020, whether a formal global goal for measles eradication should be set with timeframes for achievement













Major findings and conclusions (2)



- Disease incidence is the most important indicator of progress
- There is an urgent need to strengthen the collection and use of surveillance data to better guide program strategy and implementation
 - Outbreaks highlight program weaknesses
- Strengthening of immunization systems is critical to achieving regional elimination goals
 - Two doses of measles or measles-rubella vaccine delivered through ongoing services is the standard for national programs.
 - Regular preventative campaigns should be conducted if coverage is insufficient for high population immunity













Summary



- US still at high risk of importation due to ongoing global transmission
- Effective vaccination strategies exist, resulting in major achievements but targets *not* met
 - Midterm review:
 - "[The basic strategies are sound, however,] the main impediments to full implementation have been inadequate country ownership and global political will, reflected in inadequate resources"
- Global efforts to assist countries to introduce rubella containing vaccine are needed
- Mid-term review recommendations are being implemented to continue progress towards a world without measles, rubella and congenital rubella syndrome













Thank you from the Measles and Rubella Initiative Partners















































Japan International Cooperation Agency



international pediatric association association internationale de pédiatrie asociación Internacional de pediatría

